查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1857907

局部性節段性腎小球硬化症市場按藥物類別、分期、最終用戶和患者類型分類 - 全球預測 2025-2032

Focal Segmental Glomerulosclerosis Market by Drug Class, Stage, End-Use, Patient Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，局部節段性腎絲球硬化症市場規模將達到 36.9 億美元，複合年成長率為 8.07%。

關鍵市場統計數據
基準年 2024 19.8億美元
預計年份：2025年 21.3億美元
預測年份 2032 36.9億美元
複合年成長率 (%) 8.07%

本書以臨床為導向，介紹局部節段性腎絲球硬化症，重點闡述診斷的複雜性、治療重點以及如何為相關人員建立多學科診療路徑。

局部節段性腎小球硬化症 (FSGS) 是衛星群的總稱，其特徵為足細胞損傷、腎小球內節段性硬化和進行性蛋白尿，常導致慢性腎功能障礙。臨床上，FSGS 的病因多種多樣，從特發性機製到繼發性病因，包括感染疾病、藥物、腎單位缺失的適應性反應以及基因突變等。因此，FSGS 的診斷需要綜合考慮臨床症狀、實驗室檢查（包括蛋白尿和生物標記的定量）以及切片檢查的組織病理學確診。

目前的臨床治療重點在於盡可能找出並解決潛在原因，同時採取支持性措施保護腎臟。血壓控制和透過調節腎素-血管收縮素系統來減少蛋白尿是基礎治療。糖皮質激素治療仍然是許多患者的主要治療手段，尤其是在對荷爾蒙敏感的疾病中；然而，不利事件和療效差異凸顯了開發其他治療策略的必要性。在整個醫療保健系統中，整合腎臟病學、病理學、遺傳學及相關專科的多學科診療模式對於最佳化治療效果、預防疾病進展以及控制水腫、高血脂症和血栓風險等併發症的重要性日益凸顯。

隨著該領域的發展，相關人員臨著科學發現、不斷演變的法規和以病人為中心的期望之間動態的相互作用。本導言概述了局部節段性腎小球硬化症（FSGS）的臨床和營運現狀，重點強調了將診斷的複雜性、治療重點和研究進展與日常實踐的可行路徑相結合的必要性。

局部節段性腎絲球硬化症的臨床、診斷和轉化醫學方面的變革性轉變正在重塑治療策略、試驗設計和多學科護理模式。

局部節段性腎絲球硬化症的治療模式正在經歷一場變革性的轉變，這主要得益於科學、技術和醫療服務三方力量的融合。在生物學層面，基因組學和分子病理學的進步揭示了不同的機制亞型，使得治療方法。這些分子層面的發現加速了潛在的類固醇替代療法和緩解疾病標靶的識別，並重新調整了臨床試驗的入組標準，使其更加關注生物學同質性較高的患者群體。

同時，從精細化的免疫組化檢測、數位病理學到輔助病變分類的機器學習演算法等診斷工具的創新，正在提高診斷的一致性並降低觀察者間的差異。這些工具支持更早期、更準確的診斷，進而指導治療順序和監測策略。臨床試驗設計也在同步發展，改良的方案、富含生物標記的隊列以及患者報告結局終點等，正成為實證醫學範式中日益重要的特徵。

醫療保健系統和支付方的動態變化也在再形成決策路徑。隨著治療方法選擇的增多，其價值、療效持久性和實際療效正受到越來越多的檢視。醫療服務提供者正在採取整合式照護路徑，強調腎臟保護、併發症管理和照護協調，以降低後續併發症的發生率。病患權益倡導和數位化參與提高了疾病認知度和臨床試驗參與率，學術中心、生物技術創新者和診斷公司之間的合作正在推動轉化醫學的進步。這些轉變共同營造了一種局面，在這種局面下，精準醫療和主導醫學的應用將對患者的治療結果產生長期影響。

一項基於證據的評估，旨在了解美國在 2025 年實施的關稅政策如何影響局部節段性腎小球硬化症管理的供應鏈、籌資策略和臨床連續性。

美國2025年關稅的實施對局部節段性腎絲球硬化症（FSGS）生態系統產生了多方面的影響，波及供應鏈物流、籌資策略和治療經濟等各個環節。製藥公司和經銷商面臨進口活性原料藥和特殊成分的短期成本調整，迫使許多機構重新評估籌資策略和庫存緩衝。依賴國際供應鏈取得關鍵治療藥物、診斷試劑、切片檢查處理材料等的醫院和診所不得不調整其採購和庫存管理方式，以維持醫療服務的連續性，避免治療流程中斷。

為因應不斷上漲的進口相關成本，多個相關人員加快了本地化生產和供應商多元化的步伐。這項轉變促成了更具策略性的採購夥伴關係，並更加重視區域製造中心，以減輕關稅和物流不確定性的影響。同時，支付方和採購集團也加強了對採購成本的審查，這影響了處方談判和合約簽訂方式。政策因應措施和機構合約也隨之調整，優先考慮供應安全和可預測的定價機制，這與旨在保障基本醫療供應鏈的國內製造獎勵和公私合作的長期討論相一致。

在臨床方面，對病患的直接影響主要集中在採購替代風險和系統調整期間可能帶來的行政負擔。然而，從長遠來看，這為提升供應韌性、加強臨床醫生、供應鏈領導者和製造商之間的夥伴關係提供了機會。這些調整強調採購透明度、加快供應商資質認證流程以及投資於生產冗餘，所有這些都有助於在不斷變化的貿易環境下，為FSGS治療的持續進行奠定更堅實的基礎。

深度分割智慧揭示了藥物類別、疾病階段、治療環境和患者屬性如何共同影響局部節段性腎小球硬化症（FSGS）的治療路徑和實證醫學優先事項。

分段分析為理解局部節段性腎小球硬化症 (FSGS) 的治療方法選擇和護理路徑提供了至關重要的細節，每個維度都揭示了不同的臨床和商業考慮。藥物類別包括血管收縮素酶抑制劑、血管收縮素受體阻斷劑和糖皮質激素，這反映了它們在腎臟保護、減少蛋白尿和免疫調節方面的不同作用。原發性疾病與次發性疾病的區分突顯了基於疾病分期的病因和治療策略的差異。原發性疾病通常需要免疫抑制和標靶治療，而次發性疾病則需要在保護腎臟的同時治療原發性疾病。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 透過生物標記主導的FSGS患者分層進行標靶治療，推進精準醫療
  • 對基因編輯技術的投資不斷增加，重點在於與FSGS易感性相關的APOL1基因突變。
  • 開發新型內皮素受體拮抗劑，這些拮抗劑在FSGS的臨床試驗中顯示出腎臟保護作用。
  • 擴展以患者為中心的數位健康平台，用於遠端監測和管理FSGS進展
  • 加強學術界與生技公司之間的合作，加速早期局部性節段性腎絲球硬化症（FSGS）藥物研發進程。
  • 兒童局部節段性腎絲球硬化症（FSGS）盛行率的增加推動了針對特定年齡層治療方案的需求。
  • 真實世界臨床試驗的出現，檢驗新型FSGS治療的長期安全性和有效性。
  • FDA突破性療法認定加速創新FSGS生物製藥和小分子藥物的法規核准路徑
  • 採用脂質體藥物傳遞系統增強腎臟標靶性並降低治療局部性節段性腎小球硬化症（FSGS）的脫靶毒性。
  • 合約研究機構 (CRO) 與製藥公司之間策略夥伴關係的激增，旨在最佳化局部節段性腎小球硬化症 (FSGS) 臨床試驗

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類別分類的局部節段性腎絲球硬化症市場

  • 血管收縮素酶抑制劑
  • 血管收縮素受體阻斷劑
  • 皮質類固醇

9. 局部節段性腎絲球硬化症市場（依階段分類）

  • 基本的
  • 次發性

10. 依最終用途分類的局部節段性腎絲球硬化症市場

  • 診所
  • 醫院

11. 依病患類型分類的局部節段性腎絲球硬化症市場

  • 成人
  • 孩子們

12. 區域性局部性節段性腎絲球硬化症市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 局部節段性腎絲球硬化症市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國局灶節段性腎絲球硬化症市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Alkem Laboratories Ltd.
    • Bristol Myers Squibb Company
    • Certa Therapeutics Pty Ltd.
    • Cipla Ltd.
    • CMG Biotech Pvt. Ltd.
    • Dr Reddy's Laboratories Ltd.
    • Fresenius Kabi Pvt. Ltd.
    • GSK PLC
    • Hikma Pharmaceuticals PLC
    • Intas Pharmaceuticals Ltd.
    • Lupin Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd
    • Pfizer, Inc.
    • Sanofi SA
    • Travere Therapeutics, Inc.
    • Vera Therapeutics Inc.
Product Code: MRR-C002B1C994EF

The Focal Segmental Glomerulosclerosis Market is projected to grow by USD 3.69 billion at a CAGR of 8.07% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.98 billion
Estimated Year [2025] USD 2.13 billion
Forecast Year [2032] USD 3.69 billion
CAGR (%) 8.07%

A clinically oriented introduction to focal segmental glomerulosclerosis that frames diagnostic complexity, therapeutic priorities, and multidisciplinary care pathways for stakeholders

Focal segmental glomerulosclerosis (FSGS) represents a constellation of clinicopathologic processes characterized by podocyte injury, segmental sclerosis within glomeruli, and progressive proteinuria that frequently culminates in chronic kidney impairment. Clinicians encounter FSGS across a spectrum of etiologies ranging from idiopathic mechanisms to secondary causes tied to infections, medications, adaptive responses to reduced nephron mass, and genetic variants. Consequently, diagnosis demands a synthesis of clinical presentation, laboratory assessment including proteinuria quantification and biomarkers when available, and histopathologic confirmation through renal biopsy, where podocyte effacement and segmental scarring remain key diagnostic hallmarks.

Current clinical management hinges on addressing the underlying cause where identifiable while applying supportive renal protective measures. Blood pressure control and mitigation of proteinuria through renin-angiotensin system modulation constitute foundational care. Corticosteroid therapy continues to play a central role for many patients, particularly in steroid-responsive disease, yet the adverse event profile and variable response rates underscore the need for additional therapeutic strategies. Across health systems, multidisciplinary care models that integrate nephrology, pathology, genetics, and allied specialties are increasingly pivotal to optimize outcomes, reduce progression, and manage complications such as edema, hyperlipidemia, and thrombotic risk.

As the field advances, stakeholders face a dynamic interplay of scientific discovery, regulatory evolution, and patient-centered expectations. This introduction frames the clinical and operational landscape of FSGS, highlighting diagnostic complexity, therapeutic priorities, and the imperative to align research momentum with pragmatic pathways for adoption in routine care.

Transformative clinical, diagnostic, and translational shifts reshaping therapeutic strategies, trial designs, and multidisciplinary care models in focal segmental glomerulosclerosis

The landscape of focal segmental glomerulosclerosis is undergoing transformative shifts driven by converging scientific, technological, and care-delivery forces. At the biological level, advances in genomics and molecular pathology have clarified distinct mechanistic subtypes, enabling a move away from one-size-fits-all approaches toward mechanism-informed therapeutic selection. This molecular resolution has accelerated the identification of targets that promise steroid-sparing or disease-modifying potential and has reframed trial enrollment criteria to focus on biologically homogeneous cohorts.

Concurrently, innovations in diagnostic modalities-from refined immunohistochemical panels to digital pathology and machine-learning algorithms that assist in lesion classification-are improving diagnostic consistency and reducing interobserver variability. These tools support earlier and more precise diagnosis, which in turn informs treatment sequencing and monitoring strategies. Trial design has evolved in parallel, with adaptive protocols, biomarker-enriched cohorts, and patient-reported outcome endpoints becoming more prominent features in evidence generation frameworks.

Health-system and payer dynamics are also reshaping decision pathways. As therapeutic options broaden, there is increased scrutiny on value, durability of response, and real-world effectiveness. Providers are adopting integrated care pathways that emphasize nephroprotection, co-morbidity management, and care coordination to reduce downstream morbidity. Patient advocacy and digital engagement have elevated disease awareness and trial participation, while collaborations among academic centers, biotech innovators, and diagnostic firms are catalyzing translational progress. Together, these shifts are creating a landscape in which precision therapeutics and evidence-driven adoption determine long-term impact on patient outcomes.

An evidence-based assessment of how United States tariff policies introduced in 2025 influenced supply chains, procurement strategies, and clinical continuity for focal segmental glomerulosclerosis management

The imposition of United States tariffs in 2025 exerts a multifaceted influence on the FSGS ecosystem, with reverberations across supply chain logistics, procurement strategies, and the economics of care. Pharmaceutical manufacturers and distributors confronted short-term adjustments to costs for imported active pharmaceutical ingredients and specialty components, prompting many organizations to reassess sourcing strategies and inventory buffers. Hospitals and clinics that rely on international supply chains for key therapeutics, diagnostic reagents, and biopsy processing materials have had to adapt purchasing and inventory management practices to maintain continuity of care and avoid disruptions in treatment pathways.

In response to increased import-related costs, several stakeholders accelerated initiatives to localize aspects of production and to diversify supplier bases. This reorientation has translated into more strategic procurement partnerships and increased interest in regional manufacturing hubs to mitigate tariff exposure and logistical volatility. At the same time, payers and purchasing groups intensified scrutiny of acquisition costs, which has influenced formulary negotiations and contracting approaches. Policy responses and institutional contracting evolved to prioritize supply security and predictable pricing mechanisms, dovetailing with longer-term conversations about domestic manufacturing incentives and public-private collaboration to secure essential medical supply chains.

Clinically, the immediate patient-facing impact centered on procurement-driven substitution risks and potential administrative burdens while systems adjusted. However, the longer-term landscape revealed opportunities for improved supply resilience and strengthened partnerships between clinicians, supply chain leaders, and manufacturers. These adaptations emphasized transparency in sourcing, the acceleration of supplier qualification processes, and investments in manufacturing redundancy, all of which contribute to a more resilient foundation for delivering uninterrupted FSGS care under shifting trade conditions.

Deep segmentation intelligence revealing how drug class, disease stage, care setting, and patient demographics converge to shape therapeutic pathways and evidence priorities in FSGS

Segmentation analysis provides essential granularity for understanding therapeutic choices and care pathways in FSGS, and each axis illuminates distinct clinical and commercial considerations. Based on Drug Class, market analysis distinguishes between Angiotensin Enzyme Inhibitors, Angiotensin Receptor Blockers, and Corticosteroids, reflecting differential roles in renoprotection, proteinuria reduction, and immunomodulation; angiotensin-modulating agents remain core to supportive therapy, while corticosteroids address immune-mediated processes but carry trade-offs related to safety and tolerability. Based on Stage, the dichotomy of Primary and Secondary disease highlights diverging etiologies and management strategies; primary disease often prompts immunosuppression and targeted interventions, whereas secondary forms demand treatment of the inciting condition alongside renal protection.

Based on End-Use, settings of care across Clinics and Hospitals shape diagnostic workflows and treatment delivery; outpatient clinics play a central role in longitudinal monitoring and chronic therapy management, whereas hospitals are pivotal for acute presentations, biopsy procedures, and initiation of intensive immunosuppressive regimens. Based on Patient Type, adults and pediatric populations present distinct clinical trajectories, dosing considerations, and long-term care needs, with pediatric cohorts requiring particular attention to growth, developmental impacts of treatment, and genetic etiologies that may influence therapeutic selection.

Integrating these segmentation lenses reveals cross-cutting imperatives: therapeutics must demonstrate favorable benefit-risk profiles across age groups and disease stages, diagnostic and treatment pathways must be adaptable to both clinic and hospital environments, and evidence generation should be stratified to address etiologic heterogeneity. Stakeholders that align development programs, clinical trial design, and commercial strategies with these segmentation realities are positioned to address unmet needs more precisely and to facilitate adoption in the appropriate care settings.

Comprehensive regional analysis highlighting divergent diagnostic capabilities, clinical research ecosystems, and access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a pronounced influence on how FSGS is diagnosed, treated, and researched, and recognizing these differences is essential for global strategy. In the Americas the healthcare landscape features advanced nephrology networks, strong transplant programs, and concentrated centers of clinical research that drive protocol development and trial participation; reimbursement frameworks and payer expectations in this region often shape pricing models and access pathways for new therapies. Europe, Middle East & Africa displays substantial heterogeneity across health systems, with well-resourced markets offering rapid adoption in specialist centers while other locations contend with limited diagnostic capacity, constrained access to biopsy services, and variable reimbursement pathways that affect treatment availability.

In Asia-Pacific the combination of large patient populations, expanding clinical research capacity, and diverse regulatory environments creates both opportunity and complexity; several jurisdictions are investing heavily in diagnostic infrastructure and precision-medicine initiatives, which supports enrollment in biomarker-driven studies and accelerates local evidence generation. Across regions, differences in genetic backgrounds, environmental exposures, and patterns of secondary causes influence epidemiology and clinical presentation, necessitating region-specific approaches to guideline development, trial design, and patient engagement. Moreover, regional supply chain configurations and procurement practices affect the availability and continuity of specialized therapies and diagnostic reagents, underscoring the importance of tailored commercialization plans and partnerships that reflect local regulatory, reimbursement, and care-delivery realities.

Strategic corporate behaviors and partnership models driving therapeutic innovation, diagnostic integration, and payer alignment to support differentiated approaches in focal segmental glomerulosclerosis

Company strategies in the FSGS domain reflect a blend of clinical ambition and pragmatic alignment with regulatory and payer expectations. Innovators are prioritizing pipeline programs that target molecularly defined mechanisms with the potential to alter disease course or reduce reliance on broad immunosuppression. These programs often pair therapeutic development with companion diagnostics or biomarker strategies to enable more precise patient selection and to demonstrate differentiated value in clinical trials. At the same time, established pharmaceutical firms are leveraging scale and distribution networks to optimize access for existing standard-of-care therapies while exploring combination approaches or label expansions that address unmet subpopulations.

Strategic partnerships are common, with biopharma collaborating with diagnostic developers, academic centers, and contract research organizations to accelerate translational milestones and streamline trial execution. Commercial strategies emphasize early engagement with payers and health technology assessment bodies to clarify evidence requirements and to design post-approval evidence-generation plans. Additionally, manufacturers are investing in patient support programs, digital adherence tools, and provider education to facilitate optimal use and monitoring of therapies. Competitive dynamics also reflect the role of generics and established antihypertensive agents within supportive care, necessitating clear positioning and outcomes data for novel interventions to justify differentiated adoption in clinical practice.

Actionable and integrated recommendations for industry leaders to align development, diagnostics, payer engagement, and supply resilience for optimized FSGS program execution

Industry leaders should adopt a set of actionable priorities to navigate the evolving FSGS landscape and to translate scientific advances into improved patient outcomes. First, align clinical development programs with mechanism-based patient stratification to increase the likelihood of meaningful clinical responses and to streamline regulatory discussions. Second, pair therapeutic programs with robust biomarker and diagnostic strategies to facilitate patient selection, monitoring, and value demonstration in payer dialogues. Third, invest in decentralized and hybrid trial designs that lower participation barriers and that capture real-world effectiveness across diverse populations.

Fourth, strengthen collaborations with nephrology centers of excellence and patient advocacy groups to enhance recruitment, capture patient-reported outcomes, and ensure that trial endpoints reflect clinically meaningful benefits. Fifth, proactively engage payers and health technology assessment bodies early in the development cycle to define acceptable evidence thresholds and to design post-approval evidence-generation that supports reimbursement. Sixth, implement supply-chain resilience measures, including diversified sourcing and regional manufacturing partnerships, to mitigate risks from trade policy shifts and logistical disruptions.

Seventh, develop comprehensive education and support programs for clinicians and patients to optimize initiation, monitoring, and adherence to novel regimens, with particular attention to pediatric considerations and comorbidity management. Eighth, incorporate health-economic analyses and real-world evidence plans into launch strategies to demonstrate long-term value to stakeholders. By executing this integrated set of actions, industry teams can reduce adoption friction, enhance patient benefit, and create durable pathways for sustainable therapeutic uptake.

A rigorous multi-method research methodology combining clinical literature, trial registry mapping, expert interviews, and real-world evidence synthesis with transparent quality controls

This analysis synthesized a multi-source research methodology to ensure robustness, transparency, and replicability in deriving strategic insights. The approach combined systematic literature review of peer-reviewed clinical and translational studies, analysis of public regulatory documents and clinical trial registries to map evidence generation trends, and structured interviews with nephrology clinicians, pathology experts, and health-system leaders to validate key assumptions and operational realities. Real-world evidence inputs-including aggregated observational data, registries, and claims-based analyses where publicly available-were triangulated with clinical trial findings to contextualize treatment patterns and diagnostic utilization.

The research also incorporated landscape mapping of therapeutic candidates, diagnostics, and service delivery models, supported by analysis of reimbursement frameworks and procurement practices across major jurisdictions. Quality assurance processes included independent review by clinical subject-matter experts, consistency checks across data sources, and transparent documentation of inclusion criteria and evidence limitations. Where gaps in public evidence existed, insights relied on expert consensus and scenario-based reasoning, with clear annotation of inferential assumptions. Limitations to note include variability in biopsy utilization and diagnostic coding practices across systems, and the evolving nature of therapeutic pipelines that may outpace published evidence; these factors were addressed through sensitivity in interpretation and emphasis on mechanism-driven trends rather than quantitative forecasts.

A concise, integrative conclusion summarizing how scientific advances, diagnostic precision, and systemic resilience will determine the future care pathways for FSGS

Focal segmental glomerulosclerosis occupies a complex intersection of unmet clinical need, advancing scientific understanding, and shifting healthcare dynamics. Diagnostic precision and mechanistic stratification are redefining how clinicians conceptualize FSGS subtypes, and this evolution enables more targeted therapeutic approaches that may reduce reliance on broadly immunosuppressive regimens. Concurrent innovations in diagnostics, trial design, and care delivery are facilitating earlier and more individualized interventions, while supply-chain and policy developments underscore the importance of operational resilience.

For stakeholders across the ecosystem, the imperative is to translate mechanistic insights into pragmatic clinical pathways that account for heterogeneity in patient populations, care settings, and regional systems. Strategic alignment among developers, payers, providers, and patient communities-anchored by robust evidence generation and clear value communication-will determine which innovations reach routine practice and which remain constrained to niche settings. Ultimately, the trajectory for FSGS care depends on coordinated efforts to couple scientific advances with implementation strategies that prioritize patient benefit, equitable access, and long-term sustainability within health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advances in precision medicine with biomarker-driven FSGS patient stratification for targeted therapies
  • 5.2. Rising investment in gene editing technologies focusing on APOL1 gene variants associated with FSGS susceptibility
  • 5.3. Development of novel endothelin receptor antagonists demonstrating nephroprotective effects in FSGS clinical studies
  • 5.4. Expansion of patient-centric digital health platforms for remote monitoring and management of FSGS progression
  • 5.5. Increasing collaboration between academia and biotech firms to accelerate early-stage FSGS drug discovery pipelines
  • 5.6. Growing prevalence of FSGS in paediatric populations driving demand for age-specific therapeutic formulations
  • 5.7. Emergence of real-world evidence studies to validate long-term safety and efficacy of emerging FSGS treatments
  • 5.8. FDA breakthrough therapy designations accelerating regulatory paths for innovative FSGS biologics and small molecules
  • 5.9. Adoption of liposomal drug delivery systems to enhance renal targeting and reduce off-target toxicity in FSGS therapies
  • 5.10. Surge in strategic partnerships between CROs and pharma companies for FSGS clinical trial optimization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Focal Segmental Glomerulosclerosis Market, by Drug Class

  • 8.1. Angiotensin Enzyme Inhibitors
  • 8.2. Angiotensin Receptor Blockers
  • 8.3. Corticosteroids

9. Focal Segmental Glomerulosclerosis Market, by Stage

  • 9.1. Primary
  • 9.2. Secondary

10. Focal Segmental Glomerulosclerosis Market, by End-Use

  • 10.1. Clinics
  • 10.2. Hospitals

11. Focal Segmental Glomerulosclerosis Market, by Patient Type

  • 11.1. Adults
  • 11.2. Pediatric

12. Focal Segmental Glomerulosclerosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Focal Segmental Glomerulosclerosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Focal Segmental Glomerulosclerosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Alkem Laboratories Ltd.
    • 15.3.2. Bristol Myers Squibb Company
    • 15.3.3. Certa Therapeutics Pty Ltd.
    • 15.3.4. Cipla Ltd.
    • 15.3.5. CMG Biotech Pvt. Ltd.
    • 15.3.6. Dr Reddy's Laboratories Ltd.
    • 15.3.7. Fresenius Kabi Pvt. Ltd.
    • 15.3.8. GSK PLC
    • 15.3.9. Hikma Pharmaceuticals PLC
    • 15.3.10. Intas Pharmaceuticals Ltd.
    • 15.3.11. Lupin Ltd.
    • 15.3.12. Merck & Co., Inc.
    • 15.3.13. Novartis AG
    • 15.3.14. Otsuka Pharmaceutical Co., Ltd
    • 15.3.15. Pfizer, Inc.
    • 15.3.16. Sanofi S.A.
    • 15.3.17. Travere Therapeutics, Inc.
    • 15.3.18. Vera Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 71. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 73. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 82. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 84. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 92. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 94. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 113. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 115. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 122. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 124. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 126. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 132. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 133. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 134. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 135. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 136. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 137. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 154. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 155. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 156. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 157. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 158. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 159. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 164. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 165. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 166. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 167. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 168. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 169. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 186. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 187. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 188. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 189. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 196. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 197. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 198. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 199. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 206. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 207. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 208. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 209. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 217. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 219. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 223. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 225. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 227. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 233. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 235. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 241. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 243. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 257. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 259. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 265. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 267. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 272. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 273. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 275. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 280. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 281. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 282. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 283. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 287. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 289. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 291. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 296. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 297. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 298. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 299. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 304. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 305. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 306. INDIA FOCAL SEGMENTAL GLOMERULOSCLE